Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022015414
Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and often incurable disease. To uncover therapeutic vulnerabilities, we first developed T-ALL patient-derived tumor-xenografts (PDX) and exposed PDX cells to a library of 433 clinical-stage compounds in… read more here.
Keywords: drug responses; interactions remodel; leukemia interactions; endothelial leukemia ... See more keywords